Daily Stock Analysis, ADXS, Advaxis Inc, priceseries

Advaxis Inc. Daily Stock Analysis
Stock Information
Open
3.30
Close
3.48
High
3.57
Low
3.31
Previous Close
3.31
Daily Price Gain
0.17
YTD High
10.80
YTD High Date
Apr 1, 2019
YTD Low
2.93
YTD Low Date
Jan 2, 2019
YTD Price Change
-0.94
YTD Gain
-21.36%
52 Week High
30.60
52 Week High Date
May 15, 2018
52 Week Low
2.71
52 Week Low Date
Dec 20, 2018
52 Week Price Change
-20.82
52 Week Gain
-85.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 28. 2017
95.10
Sep 11. 2017
103.16
9 Trading Days
8.48%
Link
Company Information
Stock Symbol
ADXS
Exchange
NasdaqGS
Company URL
http://www.advaxis.com
Company Phone
732 545 1590
CEO
Daniel J. O'Connor
Headquarters
New Jersey
Business Address
305 COLLEGE ROAD EAST, PRINCETON,, NJ 08540
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001100397
About

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company's platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Description

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; and MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor. The company also has a licensing agreement with Global BioPharma Inc.; co-development and commercialization agreement with Especificos Stendhal SA de CV; and collaboration agreement with Amgen Inc. for the development and commercialization of ADXS-NEO, a preclinical investigational cancer immunotherapy treatment that activates patient's immune system to respond against mutations or neoepitopes. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.